Recursion Reports Thin Mid-Stage Efficacy Data for Rare Brain Disease Therapy

Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine the need for an additional study.